These data imply that secretory NPC2 and free cholesterol may potentially be useful for personalized precision medicine in diagnosing the sorafenib response and developing anti-sorafenib-resistant liver cancer pharmaceuticals. The gene discussed is NPC2; the disease is liver cancer.